Clovis to Apply for Expanded FDA Approval for Rubraca in Ovarian Cancer Patients
News
Clovis Oncology plans to apply to the U.S. Food and Drug Administration (FDA) for expanded approval of Rubraca (rucaparib) as a second-line and later maintenance treatment for all women with ... Read more